Morgan Stanley analyst Terence Flynn raised the target price in Bristol Myers (BMY) to $40 from $37 and maintains an Underweight rating on the stock. 2026 revenue and EPS guidance was above consensus, but was driven by higher-than-expected Eliquis guidance, analyst tells investors in research note.
Claim 50% Off TipRanks Premium
-
Unlock hedge fund-level data and powerful investment tools to make smarter, more accurate decisions
-
Stay ahead of the market with the latest news and analysis and maximize the potential of your portfolio
First published in the fly – the definitive source of breaking financial news that moves the market in real time. Try it now >>
See today’s best-performing stocks on TipRanks >>
Read more about BMY:
Disclaimer and disclosure Report a problem
-
Trump Trade: Argentina says the US will cut hundreds of tariffs
-
Bristol Myers price target raised to $68 from $64 at BofA
-
Bristol Myers price target raised to $72 from $62 at the Guggenheim
-
Bristol Myers price target raised to $64 from $60 at Citi
-
Bristol Myers price target raised to $60 from $55 at Wells Fargo